Jan 11, 2024 / 12:30AM GMT
Richard Mayland JPMorgan Chase&Co.-Analyst
Good afternoon, everyone. Thanks for joining us here today. I'm [Richard Mayland] , and I'm an associate on the Healthcare Investment Banking team. It's my pleasure to introduce Madrigal Pharmaceuticals today. We're excited to be here with CEO, Bill Sibold. With that, Bill, I'll turn it over to you.
Bill Sibold - Madrigal Pharmaceuticals Inc - Chief Executive Officer
Thanks, Richard. It's a first of all, real pleasure to be here. I'd like to thank JPMorgan for having us. This is my first JPMorgan as the CEO of Madrigal, and it's an exciting time for us as we approach a March 14 due for date.
A very rare thing in the industry and to be able to be potentially the first product to be approved in NASH in the United States ever. It's a exciting time for us here forward looking statements, and I thought I would start here to really talk a little bit about the problem that we're trying to solve.
And NASH is a very I would say, poorly recognized disease and the severity of it.
Madrigal Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers